BACKGROUND AND PURPOSE: Reconstruction of first-pass bolus information to derive regional cerebral blood volume (rCBV) maps is commonly performed in many centers; however, various protocols with different doses of paramagnetic contrast injections have been reported. We evaluated the dose dependency of rCBV maps in a brain tumor population by using three different doses of gadodiamide injection to evaluate their diagnostic accuracy in blinded reader sessions. METHODS:Eighty-three patients with intraaxial brain tumors (72 gliomas) were studied at three centers and randomized to receive a bolus injection of 0.1, 0.2, or 0.3 mmol/kg per body weight of gadodiamide. rCBV maps were generated from T2*-weighted gradient-echo echoplanar sequences at 1.5 T. Data processing was performed according to the indicator dilution theory. RESULTS: The mean contrast-to-noise ratio (CNR) was significantly different between gadodiamide doses of 0.1 and 0.2 mmol/kg (CNR = 8.7 and 15.7) and between 0.1 and 0.3 mmol/kg (CNR = 17.7). No significant difference was found between doses of 0.2 and 0.3 mmol/kg. Sensitivity for the differentiation of benign and malignant brain tumors was 80%, 95%, and 91%, and specificity was 45%, 54%, and 43% by blinded readings at 0.1, 0.2, and 0.3 mmol/ kg, respectively, as compared with histologic findings. Nonblinded readings had a sensitivity of 83%, 100%, and 90% and a specificity of 82%, 100%, and 73% at 0.1, 0.2, and 0.3 mmol/kg, respectively. CONCLUSION: A dose of 0.2 mmol/kg of gadodiamide is recommended for reconstruction of rCBV maps if data are acquired with the T2*-weighted protocol described.
RCT Entities:
BACKGROUND AND PURPOSE: Reconstruction of first-pass bolus information to derive regional cerebral blood volume (rCBV) maps is commonly performed in many centers; however, various protocols with different doses of paramagnetic contrast injections have been reported. We evaluated the dose dependency of rCBV maps in a brain tumor population by using three different doses of gadodiamide injection to evaluate their diagnostic accuracy in blinded reader sessions. METHODS: Eighty-three patients with intraaxial brain tumors (72 gliomas) were studied at three centers and randomized to receive a bolus injection of 0.1, 0.2, or 0.3 mmol/kg per body weight of gadodiamide. rCBV maps were generated from T2*-weighted gradient-echo echoplanar sequences at 1.5 T. Data processing was performed according to the indicator dilution theory. RESULTS: The mean contrast-to-noise ratio (CNR) was significantly different between gadodiamide doses of 0.1 and 0.2 mmol/kg (CNR = 8.7 and 15.7) and between 0.1 and 0.3 mmol/kg (CNR = 17.7). No significant difference was found between doses of 0.2 and 0.3 mmol/kg. Sensitivity for the differentiation of benign and malignant brain tumors was 80%, 95%, and 91%, and specificity was 45%, 54%, and 43% by blinded readings at 0.1, 0.2, and 0.3 mmol/ kg, respectively, as compared with histologic findings. Nonblinded readings had a sensitivity of 83%, 100%, and 90% and a specificity of 82%, 100%, and 73% at 0.1, 0.2, and 0.3 mmol/kg, respectively. CONCLUSION: A dose of 0.2 mmol/kg of gadodiamide is recommended for reconstruction of rCBV maps if data are acquired with the T2*-weighted protocol described.
Authors: W Weber; P Bartenstein; M W Gross; D Kinzel; H Daschner; H J Feldmann; G Reidel; S I Ziegler; C Lumenta; M Molls; M Schwaiger Journal: J Nucl Med Date: 1997-05 Impact factor: 10.057
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi Journal: AJR Am J Roentgenol Date: 1998-12 Impact factor: 3.959
Authors: L M Hamberg; P Boccalini; G Stranjalis; G J Hunter; Z Huang; E Halpern; R M Weisskoff; M A Moskowitz; B R Rosen Journal: Magn Reson Med Date: 1996-02 Impact factor: 4.668
Authors: H J Aronen; I E Gazit; D N Louis; B R Buchbinder; F S Pardo; R M Weisskoff; G R Harsh; G R Cosgrove; E F Halpern; F H Hochberg Journal: Radiology Date: 1994-04 Impact factor: 11.105
Authors: R Bruening; K K Kwong; M J Vevea; F H Hochberg; L Cher; G R Harsh; P T Niemi; R M Weisskoff; B R Rosen Journal: AJNR Am J Neuroradiol Date: 1996-05 Impact factor: 3.825
Authors: Tavarekere N Nagaraja; Vijaya Nagesh; James R Ewing; Polly A Whitton; Joseph D Fenstermacher; Robert A Knight Journal: Magn Reson Imaging Date: 2006-11-07 Impact factor: 2.546
Authors: Robert A Knight; Kishor Karki; James R Ewing; George W Divine; Joseph D Fenstermacher; Clifford S Patlak; Tavarekere N Nagaraja Journal: J Cereb Blood Flow Metab Date: 2009-03-25 Impact factor: 6.200
Authors: Rouzbeh Banan; Arash Akbarian; Majid Samii; Amir Samii; Helmut Bertalanffy; Ulrich Lehmann; Christian Hartmann; Roland Brüning Journal: PLoS One Date: 2021-08-04 Impact factor: 3.240